# Clinical Trials Data EGFR - Document 100

# Pre Operative Trastuzumab in Operable Breast Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01785420

"eligibilityCriteria": "Inclusion Criteria:a.\n\n1. Female subjects aged 18 years or older.\n2. Histologically and/or cytologically confirmed diagnosis of breast cancer. Clinical stages breast cancer: HER2 positive, T1 or T2 or T3, N0 or N1, resectable T4, or resectable N2, (all M0)\n3. Documentation of erbB-2 gene amplification by FISH (as defined by a ratio \\>2.2) or chromogenic in situ hybridization (CISH, as defined by the manufacturer's kit instruction) or documentation of erbB-2-overexpression by IHC (defined as IHC3+, or IHC2+ with FISH or CISH confirmation) based on local laboratory.\n4. LVEF within institutional range of normal as measured by MUGA or ECHO.\n5. Screening laboratory values within the following parameters:\n\n 1. Absolute neutrophil count (ANC) \u22651.5 x 109 /L (1500/mm3)\n 2. Platelet count \u2265100 x 109/L (100,000/mm3)\n 3. Hemoglobin \u22659.0 g/dL (90 g/L)\n 4. Serum creatinine \u22641.5 x upper limit of normal (ULN)\n 5. Total bilirubin \u22641.5 x ULN (\\<3 ULN if Gilbert's disease) 6Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)\n\n \* 2.5 x ULN\n\nExclusion Criteria:\n\n1. Bilateral breast cancer\n2. Active uncontrolled cardiac disease, including cardiomyopathy, CHF (New York Heart Association \\[NYHA\\] functional classification of \u22653), unstable angina, and myocardial infarction (within 12 months of study entry).\n3. Inadequately controlled hypertension (ie, systolic blood pressure \\[BP\\] \\> 180 mm Hg or diastolic BP \\> 100 mm Hg).\n4. Family history of congenital long or short QT syndrome, Brugada syndrome or QT/QTc interval \\> 0.45 second or known history of QT/QTc prolongation or torsade de pointe (TdP).\n5. Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn's disease, malabsorption, or grade \u22652 diarrhea of any etiology at baseline).\n6. Women who are pregnant, breast-feeding.",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial is for breast cancer patients with \*\*HER2\*\* positive status, not EGFR mutations. The inclusion criteria specifically mention "erbB-2 gene amplification" (another name for HER2), which is a different gene and related to a different type of cancer. Therefore, a patient with an EGFR mutation would \*not\* be eligible for this trial.